Loading…
Employees: 17
Size Relmada Therapeutics (RLMD) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $416M, the 2829th largest of 3,117 United States companies the cockpit tracks. Shares closed at $3.90 on 6 Nov 2026.
Performance Over six months the shares fell 46.7%, against -16.2% for the median peer and -1.1% for the United States market (cap-weighted) — 4th lowest of 20 in its peer set.
Next results Next results expected around 12 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | $0 | $0 | $0 | $0 | $0 |
| EBITDA | -$65.1M | -$59.1M | -$83.9M | -$104M | -$161M |
| Net income | -$61.9M | -$57.4M | -$80.0M | -$98.8M | -$157M |
| Free cash flow | -$46.0M | -$45.8M | -$51.8M | -$51.7M | -$104M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 |
| Total debt | $0 | $0 | $0 | $0 | $0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RLMD | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +23.0% | -13.9% | highest of 21 |
| 6-month return | -46.7% | -16.2% | 4th lowest of 20 |
| Distance from 52-week high | -51.2% | -40.4% | 7th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Relmada Therapeutics RLMD | United States | $416M | -47% | n/a | n/a | n/a | n/a | n/a |
| Assembly Biosciences ASMB | United States | $416M | -31% | +125% | -12% | 1.3× | n/a | n/a |
| Jiangxi Synergy Pharmaceutical 300636.SZ | China | $414M | -16% | -2% | 3% | 3.5× | n/a | n/a |
| Anhui Sunhere Pharmaceutical Excipients 300452.SZ | China | $412M | -16% | +9% | 19% | 2.4× | -4.5% | +12.1% |
| Shaanxi Panlong Pharmaceutical 002864.SZ | China | $411M | -13% | -9% | 9% | 1.6× | -0.4% | +11.2% |
| Hansa Biopharma HNSA.ST | Sweden | $410M | +39% | -4% | -304% | 23.7× | n/a | n/a |
| Dong-A Socio 000640.KS | South Korea | $425M | -11% | +10% | 7% | 0.7× | -8.8% | +12.8% |
| Puma Biotechnology PBYI | United States | $426M | +10% | -3% | 13% | 1.5× | 2.8% | +0.3% |
| Phathom Pharmaceuticals PHAT | United States | $427M | -57% | +87% | -9% | 2.9× | n/a | n/a |
| Lifecome Biochemistry 002868.SZ | China | $428M | -51% | -24% | -6% | 7.0× | n/a | n/a |
| Shandong Sinobioway Biomedicine 002581.SZ | China | $404M | -40% | +91% | -65% | 7.8× | n/a | n/a |
| BlossomHill Therapeutics BLSM | United States | $429M | n/a | n/a | n/a | n/a | n/a | n/a |
| Beijing Centergate Technologies (Holding) 000931.SZ | China | $430M | -20% | -16% | 2% | 2.0× | 9.9% | +6.7% |
| Aarti Drugs AARTIDRUGS.NS | India | $430M | +12% | +15% | 11% | 1.6× | 19.7% | +3.5% |
| JW Pharmaceutical 001060.KS | South Korea | $402M | -28% | +10% | 14% | 0.7× | -16.9% | +7.2% |
| Guangdong Lifestrong Pharmacy 301111.SZ | China | $401M | -16% | +7% | -2% | 7.9× | n/a | n/a |
| Hyundai Bioscience 048410.KS | South Korea | $401M | -58% | +78% | -580% | 158.2× | n/a | n/a |
| Kwality Pharmaceuticals KPL.NS | India | $401M | +111% | +38% | 21% | 6.8× | n/a | n/a |
| Jiangsu Bioperfectus Technologies 688399.SS | China | $432M | -44% | -8% | -23% | 5.7× | n/a | n/a |
| Tuoxin Pharmaceutical 301089.SZ | China | $400M | -22% | +17% | -20% | 5.8× | n/a | n/a |
| Zota Health Care ZOTA.NS | India | $395M | -6% | +69% | -16% | 5.8× | n/a | n/a |